Pharvaris/$PHVS
1D1W1MYTD1Y5YMAX
Capital at risk
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
- Ticker
- $PHVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 148
- Headquarters
- Zug, Switzerland
- Website
- pharvaris.com
Pharvaris Metrics
BasicAdvanced
$2.7B
-
-$3.01
-2.33
-
Price and volume
Market cap
$2.7B
Beta
-2.33
52-week high
$43.25
52-week low
$20.65
Average daily volume
985K
Financial strength
Current ratio
11.941
Quick ratio
11.819
Long term debt to equity
0.002
Total debt to equity
0.002
Interest coverage (TTM)
-1,054.74%
Profitability
EBITDA (TTM)
-209.245
Effective tax rate (TTM)
-1.40%
Management effectiveness
Return on assets (TTM)
-42.32%
Return on equity (TTM)
-70.46%
Valuation
Price to book
8.87
Price to tangible book (TTM)
8.87
Price to free cash flow (TTM)
-13.893
Free cash flow yield (TTM)
-7.20%
Free cash flow per share (TTM)
-2.735
Growth
Earnings per share change (TTM)
-15.29%
3-year earnings per share growth (CAGR)
-1.14%
What the Analysts think about Pharvaris
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Analyst projections of the future price of Pharvaris stock.
Bulls say / Bears say
The FDA accepted Pharvaris’s NDA for deucrictibant immediate-release capsules, which could make it the first oral bradykinin B2 receptor antagonist for on-demand HAE treatment; the EMA also validated the company’s marketing application in July 2026. (ir.pharvaris.com) (Pharvaris)
Liquidity is comparatively strong for a late-stage biotech: Pharvaris reported €318 million in cash and cash equivalents at June 30, 2026, and said its $132.3 million offering extends the cash runway into 2028, supporting regulatory preparation, commercial infrastructure, and ongoing pipeline work. (pharvaris.gcs-web.com) (Pharvaris)
Pharvaris remains pre-revenue and reported a €47.8 million net loss in Q2 2026, while R&D and G&A expenses increased year over year; commercialization will likely require continued substantial spending. (pharvaris.gcs-web.com) (Nasdaq)
The May 2026 equity financing raised approximately $132.3 million through 4.46 million new shares, creating near-term dilution and demonstrating that additional capital may be needed if launch costs or development spending exceed the current runway. (pharvaris.gcs-web.com) (Pharvaris)
Despite strong clinical progress, the on-demand product remains under FDA review with a PDUFA date of April 23, 2027, while the broader AAE-C1INH program is still enrolling; delays, regulatory questions, or slower market adoption could postpone revenue generation. (pharvaris.gcs-web.com) (Pharvaris)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Pharvaris Financial Performance
Revenues and expenses
Pharvaris Earnings Performance
Company profitability
Upcoming events
No upcoming events
Pharvaris News
AllArticlesVideos
Funds containing Pharvaris
AllUSDGBPEUR
Fund name | Fund size | $PHVS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.18% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.18% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.